Trial Profile
A Phase I Study of Tetrathiomolybdate (TM) in Combination With Carboplatin and Pemetrexed in Chemo-Naive Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tetrathiomolybdate (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 17 Jul 2019 Status changed from active, no longer recruiting to completed.
- 02 Jul 2019 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 02 Jul 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.